Endothelial dysfunction in rheumatoid arthritis is improved by anti-tumor necrosis factorα treatment

European Journal of Inflammation

Volumn 2, Issue 3, 2004, Pages 113-118

  Capria, Ambrogio ^a   De Nardo, D ^a   De Sanctis, G ^a   Simonelli, A R ^a   Kroegler, B ^a   Silvestri, F ^a   Franconi, G ^a   Fontana, L ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anti TNF therapy; Endothelial dysfunction; Flow mediated vasodilation; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; BLOOD FLOW; BLOOD LEVEL; BLOOD VESSEL WALL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHESIS; INCIDENCE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASCULITIS; VASODILATATION;

EID: 9744283514     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X0400200303     Document Type: Article

References (30)

1. Del Rincón I., K. Williams, M. Stern, G. Freeman and A. Escalante. 2001. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44:2737
2. Van Doornum S., G. McColl and I.P. Wicks. 2002. Accelerated atherosclerosis - an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46:862.
3. Kaplan M. and W. McCune. 2003. New evidence for vascular disease in patients with early rheumatoid arthritis. Lancet 361:1068.
4. Solomon D., E. Karlson, E. Rimm, C. Cannuscio, L. Mandi, J.A. Manson, M. Stampfer and G. Curhan. 2003. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303.
5. Goodson N., N. Wiles, M. Lunt, E. Barrett, A. Silman and D. Symmons. 2002. Mortality in early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 46:2010.
6. Bacon P.A. and J.N. Townend. 2001. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum. 44:2707.
7. Manzi S. and M. Wasko. 2000. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann. Rheum. Dis. 59: 321.
8. Esdaile J., M. Abrahamowicz, T. Grodzicky, Y. Li, C. Panaritis, R. du Berger, R. Côté, S. Grover, P. Fortin, A. Clarke and J.L. Senécal. 2001. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthr. Rheum. 44:2331.
9. Bergholm R., M. Leirisalo-Repo, S. Vehkavaara, S. Mäkimattila, M.R. Taskinen and H. Yki-Iärvinen. 2002. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler. Thromb. Vasc Biol. 22:1637.
10. Van Doornum S., G. McColl, A. Jenkins, D. Green and I.P. Wicks. 2003. Screening for atherosclerosis in patients with rheumatoid arthritis. Comparison of two in vivo tests of vascular function. Arthritis Rheum. 48:72.
11. Bacon R., R. Stevens, D. Carruthers, S. Young and G. Kitas 2002. Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmunity Reviews 1:338.
12. Ross R. 1999. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:115.
13. Behrend D. and P. Ganz. 2002. Endothelial function: from vascular biology to clinical applications. Am. J. Cardiol. 90(S):40L.
14. Verma S. and T.J. Anderson. 2002. Fundamentals of endothelial function for the clinical cardiologist. Circulation 105:546.
15. Maini R., E. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, F. Feldman and P. Lipsky. 1999. Infliximab (chimeric anti-tumor necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932.
16. Lipsky P., D. Van der Heijde, E. St. Clair, D. Furst, F. Breedveld, J. Kalden, J. Smolen, M. Weisman, P. Emery, M. Feldmann, G. Harriman and R. Maini. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Eng. J. Med. 343:1594.
17. Klippel J. 2000. Biologic therapy for rheumatoid arthritis. N Engl J. Med. 343:1640.
18. Bathon J., R. Martin, R. Fleischmann, J. Tesser, M. Schiff, E. Keystone, M. Genovese, M. Wasko, L. Moreland, A. Weaver, J. Markenson and B. Finck. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343:1586.
19. Fichtlscherer S., L. Rössig, S. Breuer, M. Vasa, S. Dimmeler and A. Zeiher. 2001. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104:3023
20. Iachini Bellisari F., S. Gallina and R. De Caterina. 2001. Tumor necrosis factor- and cardiovascular diseases. Ital. Heart J. 2:408.
21. Corretti M., T. Anderson, E. Benjamin, D. Celermajer, F. Charbonneau, M. Creager, J. Deanfield, H. Drexler, M. Gerhard-Herman, D. Herrington, P. Vallance, J. Vita and R. Vogel. 2002. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A Report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 39:257
22. Vogel R. 2001. Measurement of endothelial funcion by brachial artery flow-mediated vasodilation. Am. J. Cardiol. 88:31.
23. Hürlimann D., A. Forster, G. Noll, F. Enseleit, R. Chenevard, O. Distler, M. Béckir, L. Spieker, M. Neidhart, B. Michel, R. Gay, T. Lüscher, S. Gay and F. Ruschitzka. 2002. Anti-tumor necrosis factor-improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184.
24. Scallon B., A. Cai, N. Solowski, A. Rosenberg, X. Song, D. Shealy and C. Wagner. 2002. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exper. Ther. 301:418.
25. Pober J. 2002. Endothelial activation: intracellular signaling pathways. Arthritis Res. 4:S109.
26. Hingorami A., J. Cross, R. Kharbanda, M. Mullen, K. Bhagat, M. Taylor, A. Donald, M. Palacios, G. Griffin, J. Deanfield, R. MacAllister and P. Vallance. 2000. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 102:994.
27. Luo Z., Y. Fujio, Y. Kureishi, R. Rudic, G. Daumerie, D. Fulton, W. Sessa and K. Walsh. 2000. Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J. Clin. Invest. 106:493.
28. Gunnett C., D. Lund, Y. Chu, R. Brooks, F. Faraci and D. Heistad. 2001. NO-dependent vasorelaxation is impaired after gene transfer of inducible NO-synthase. Arterioscler. Thromb. Vasc. Biol. 21:1281.
29. Stenvinkel P. 2001. Endothelial dysfunction and inflammation- is there a link? Nephrol. Dial. Transplant. 16:1968.
30. Pasceri V. and E. Yeh. 1999. A tale of two diseases. Atherosclerosis and rheumatoid arthritis. Circulation 100:2124.